Wechselwirkungen · Wilzin
Wilzin 50 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12
HOS-112751 · Präparat HOS-093741
Other anti-copper agents Pharmacodynamic studies were conducted in Wilson’s disease patients on the combination of Wilzin (50 mg three times daily) with ascorbic acid (1 g once daily), penicillamine (250 mg four times daily), and trientine (250 mg four times daily). They showed no significant overall effect on copper balance although mild interaction of zinc with chelators (penicillamine and trientine) could be detected with decreased faecal but increased urinary copper excretion as compared with zinc alone. This is probably due to some extent of complexion of zinc by the chelator, thus reducing the effect of both active substances. When switching a patient on chelating treatment to Wilzin for maintenance therapy, the chelating treatment should be maintained and co-administered for 2 to 3 weeks since this is the time it takes for the zinc treatment to induce maximum metallothionein induction and full blockade of copper absorption. The administration of the chelating treatment and Wilzin should be separated by at least 1 hour.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): penicillamine (HOS-086112) ascorbic acid (HOS-112735) copper (HOS-112734) trientine (HOS-112737)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-12-18T15:00:00Z · SHA-256 962b2d119eb0a35c2fa316b6eb791c3cf45b3b842423521b90ed8872dafc10cf · Passage 9233c1379ce5076d2762842c4e23d154e196b04642cb3861f28e9bdb97bc68dc · Zeichen 0–1041 im Abschnitt